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Abstract 
 
Background: Pediatric bipolar (BP)-I disorder affects a sizeable minority of children and is associated with high levels of 
morbidity. Relatively few studies have assessed the persistence of the disorder over time.  
Objective: The main aim of this study was to extend our findings from our 4-year follow-up study examining rates of 
persistence of pediatric BP-I disorder onto late adolescent years and young adulthood 5 years after our original study.  
Methods: We conducted a 1-year extension to our original prospective study of 78 youth, ages six to 17 years, with BP-I 
disorder at ascertainment, who were followed up into their adolescent and young adult years (14.9 ± 3.8). All subjects were 
comprehensively assessed with structured diagnostic interviews and psychosocial, educational, and treatment history 
assessments.  
Results: Of the 78 BP-I participating youth, 68 were re-accessioned one year following the 4-year follow-up study, thus 
effectively 5 years since the original study. Of these, 63% continued to meet full (50%) or subthreshold (13%) diagnostic 
criteria for BP-I and 18% continued to have full or subthreshold major depressive disorder. Only 19% of BP-I youth were 
euthymic at the 5-year follow up.  
Discussion: This 1-year extension study further documents the high level of persistence of pediatric BP-I from childhood 
onto late adolescence and young adulthood. The results provide compelling evidence of the morbidity and dysfunction 
associated with this disorder and its many forms.  
Clinical significance: This study adds to a small amount of literature on the persistence of pediatric BP disorder and the 
critical need for early identification and intervention. 
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Introduction 
Clinic and epidemiologic studies strongly support the 
notion that pediatric bipolar (BP)-I disorder afflicts a 
substantial number of children and adolescents, and 
its presence is associated with high levels of 
morbidity and disability (1-3). Although longitudinal 
course is a key validation criteria for any psychiatric 
disorder, relatively few studies have assessed the 
persistence of the disorder over time (4). Geller et al. 
(5) reported that 44% of children with BP-I 
continued to have the full disorder by the age of 18 
years. Birmaher et al. (6) reported a chronic course of 
pediatric BP disorder with high rates of relapse and 
recovery (63% and 82%, respectively) as well as high 
rates of persistence of subsyndromal presentations 
and episodes of depression. 
For BP disorder, remission from both mania and 
depression is relevant in follow-up studies assessing 
the patterns of persistence and remission. However, 
very few longitudinal studies of pediatric BP disorder 
have considered the many different forms of 
persistence. Such forms include not only the 
persistence of the full threshold disorder but also the 
persistence of subsyndromal states such as 
hypomania or cyclothymia. 
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We recently reported results from a 4-year follow 
up of 78 youth with the onset of pediatric BP-I 
disorder, attending to these different definitions of 
persistence (4). Findings revealed that most youth 
with BP-I disorder at baseline (73.1%) continued to 
meet full Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition (DSM-IV) diagnostic criteria 
for BP-I disorder at follow up (i.e., syndromatic 
persistence). Of the non-persistent cases, or cases 
that did not meet criteria for full BP-I disorder at 
follow up (26.9%), the overwhelming majority 
(20.5%) had signs and symptoms of ongoing illness: 
6.4% had subthreshold BP-I disorder, 5.1% had no 
mania but had full or subthreshold major depression, 
and 9% were euthymic but treated for a mood 
disorder. Considering the severity of these outcomes, 
corroboration of these findings is clinically and 
scientifically important. Longitudinal 
course/persistence is a cornerstone of the validation 
of any disorder. This report is one of only three 
longitudinal studies of pediatric BP disorder, a highly 
morbid condition. Our focus on the different forms 
of persistence is a clinically and scientifically relevant 
way to interpret longitudinal data. Few longitudinal 
studies of pediatric BP disorder have considered the 
many different forms of persistence. Such forms 
include not only the persistence of the full threshold 
disorder but also the persistence of subsyndromal 
states such as hypomania or cyclothymia. The 
persistence of full threshold and subsyndromal 
depressive and manic states, individually, has also 
been minimally explored. 
To this end, the main aim of the present study was 
2-fold: to conduct a 1-year follow-up study in which 
the methods replicate our previously reported 4-year 
follow up of our sample of pediatric BP-I disorder, 
confirming the high level of persistence documented; 
and to attend to different definitions of remission at 
follow up, including persistence of the full diagnosis 
of BP-I disorder as well as the presence of 
subsyndromal mania and depression. We 
hypothesized that the persistence of pediatric BP-I 
disorder would continue and that subsyndromal 
states would continue to be highly represented into 
adolescence. 
 
Methods 
Subjects 
We recruited 105 youths in a longitudinal follow-up 
study of BP-I disorder. Detailed study methodology 
has been previously reported (4). Potential BP-I 
disorder probands were ascertained for a family study 
of BP disorder from the Clinical and Research 
Programs in Pediatric Psychopharmacology at the 
Massachusetts General Hospital, referrals from local 
clinicians, or self-referral in response to 
advertisements. Probands were children and 
adolescents of both sexes who were six to 17 years 
old. To be included, subjects must have had a full 
lifetime DSM-IV diagnosis of BP-I disorder plus 
active symptoms of the disorder at the time of study 
entry. Subjects were excluded if they had either 
organic brain dysfunction or mental retardation (IQ 
< 70) or if their BP disorder was due solely to a 
medication reaction. All subjects’ parents or 
guardians signed written informed consent forms 
and children older than seven years of age signed 
written assent forms. All study procedures were 
reviewed and approved by the subcommittee for 
human subjects of our institution. 
 
Diagnostic procedures 
Psychiatric assessments of subjects (probands and 
first-degree family members) younger than 18 years 
were made with the Kiddie Schedule for Affective 
Disorders and Schizophrenia for School-Age 
Children, Epidemiologic Version (KSADS-E) (7). 
Assessments of those older than 18 years were made 
with the Structured Clinical Interview for DSM-IV 
(8) supplemented with modules from the KSADS-E 
to cover childhood disorders. At baseline, all subjects 
were ≤ 17 years old and were thus assessed with the 
K-SADS-E. At follow up, 53 subjects were ≤ 17 
years old and were assess with the K-SADS-E and 15 
subjects were > 17 years old and were assessed with 
the Structured Clinical Interview for DSM-IV 
supplemented by the K-SADS-E for childhood 
disorders. 
This 5-year follow-up study includes 15 subjects 
younger than 12 years whose diagnoses were 
obtained by an interview with the parent about the 
child. In addition, 53 subjects were aged 12 years or 
older, and diagnostic data on these subjects were 
obtained from two sources: a direct interview of the 
parent about the child and a direct interview of the 
child about him/herself. We combined these 
interviews such that an endorsement of a diagnosis 
in the subject by either the parent or the child resulted 
in a positive diagnosis. 
Extensively trained and supervised psycho-
metricians with undergraduate degrees in psychology 
conducted all the interviews. At the baseline clinical 
assessment, raters were blind to the study assignment 
and whether the subject was a proband or sibling. 
Siblings were studied, but not reported on in this 
study, as the original study was a family study. 
Different raters, who were also blinded, performed 
the follow-up assessments. All diagnoses were 
reviewed by a sign-off committee of experienced 
board-certified child and adolescent psychiatrists or 
clinical psychologists who were blind to the subjects’ 
ascertainment group, ascertainment site, and data 
collected from other family members. Based on 500 
interviews, the median kappa coefficient between 
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raters and clinicians was 0.99 and the median 
agreement between individual clinicians and the 
clinical review committee chaired by the principal 
investigator (PI) was 0.87. Kappa coefficients for 
individual disorders have been reported elsewhere 
(4). 
Children were determined to meet DSM-IV criteria 
for BP-I disorder according to assessments 
completed with the KSADS-E. The DSM-IV 
requires subjects to meet criterion A for a distinct 
period of extreme and persistently elevated, 
expansive, or irritable mood lasting at least one week, 
plus criterion B, manifested by three (four if the 
mood is irritable only) of seven symptoms during the 
period of mood disturbance. To ensure that the 
criterion B symptoms were concurrent with the 
criterion A mood disturbance, subjects were directed 
to focus on the worst or most impairing episode of 
mood disturbance while being assessed for the 
presence of the confirmatory criterion B symptoms. 
That is, the subject was asked to consider the time 
during which the criterion A mood disturbance was 
at its worst for the purposes of determining whether 
the remaining criterion B symptoms were also 
evident at the same time as the mood disturbance. 
The onset of first episode, the number of episodes, 
the offset of the last episode, and the total duration 
of the illness were also recorded. Any subject meeting 
criteria for BP-II or BP disorder not otherwise 
specified (BP-NOS) was not included in this study. 
To gauge a distinct episode, our interviewers asked 
for “a distinct period (of at least one week) of 
extreme and persistently elevated, expansive, or 
irritable mood” and further required that the 
irritability endorsed in this module was “super” and 
“extreme.” 
To meet for a subthreshold diagnosis of mania, a 
child must have met criterion A for a period of four 
days or longer, and/or have at least two (three if the 
mood is irritable only) of the seven criterion B 
symptoms and associated impairment. One-year 
prevalence of a disorder was defined as positive if the 
subject met criteria for a given disorder in the year 
before the time of the 5-year follow up. To meet for 
a subthreshold diagnosis of depression, a child must 
have met criterion A for a period of one week or 
longer, and/or have at least three of the criterion B 
symptoms and associated impairment. 
We also examined levels of impairment. For the 
KSADS-E, once a diagnosis was established as full 
or subthreshold, the rater assigned a severity 
designation (mild, moderate, or severe), for both past 
and current diagnoses, based on the clinical material 
presented. All severity designations were reviewed by 
the same sign-off committee of experienced board-
certified child and adolescent psychiatrists or clinical 
psychologists who reviewed the diagnoses. 
Other subject characteristics 
Socioeconomic status (SES) was measured using the 
5-point Hollingshead scale (9). We used the DSM-IV 
Global Assessment of Functioning (GAF) to 
measure overall level of functioning within the last 
month (current functioning) (7). Questions regarding 
academic functioning (tutoring, repeated grades, and 
placement in special class) were also asked during the 
interview. 
 
Group assignment 
Persistence of subjects returning for the 5-year 
follow up was described as syndromatic persistence 
(full BP-I disorder criteria met in the past year) or 
symptomatic persistence (subthreshold BP-I 
disorder or full or subthreshold major depression in 
the past year). Remission of subjects was described 
as syndromatic and symptomatic remission, or in 
other words, euthymic. Remission was defined as 
without full or subthreshold diagnoses of major 
depression or mania in the previous year. One-year 
prevalence was defined as positive if the subject met 
the criteria for a given disorder in the year before the 
time of the 5-year follow up. 
 
Statistical analysis 
We first compared demographics between those lost 
to follow up and those who returned for follow up 
using Student’s t-tests for continuous measures, 
Pearson’s chi-square or Fisher’s exact tests (if 
expected counts were < 5) for dichotomous 
measures, and Wilcoxon rank-sum tests for ordinal 
measures. Next, we compared demographic 
characteristics among subjects with syndromatic 
persistence, symptomatic persistence, and 
syndromatic or symptomatic remission using logistic 
regression for binary outcomes, exact logistic 
regression for binary outcomes with zero-cells, linear 
regression for continuous outcomes, and ordered 
logistic regression for ordinal outcomes. We then 
examined specific characteristics of BP disorder. For 
baseline and lifetime duration and number of 
episodes, the variances were higher than the means 
within each group, indicating that over-dispersion 
was present in the data. Therefore, we analyzed 
baseline and lifetime duration and number of 
episodes using negative binomial regression, that is, 
Poisson regression with an extra parameter to test for 
over-dispersion. We analyzed the number of 
symptoms and severe impairment at baseline using 
linear and logistic regression, respectively. 
We compared subjects’ overall level of functioning 
within the past month using linear regression and 
school functioning outcomes using logistic 
regression. Additionally, we analyzed the 1-year 
prevalence of comorbid psychiatric disorders and 
family history of psychiatric disorders using logistic 
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regression or, in the event of zero-cells or expected 
counts less than five, exact logistic regression. We 
used logistic regression with robust standard errors 
to account for the non-independence of family 
members to compare rates of mood disorders in 
first-degree relatives of probands. All analyses were 
two tailed and performed at the 0.05 alpha level using 
Stata® (Version 14). 
 
Results 
Subject characteristics and retention/attrition 
Of the 78 subjects at the 4-year follow up, 68 (87%) 
returned for the 5-year follow up. There were no 
differences in baseline age (9.7 ± 3.5 vs. 10.6 ± 3.3 
years; t103 = –1.27; = 0.21), sex (75% male vs. 86% 
male; χ2 = 1.91; p = 0.17), or functional impairment 
(GAF score: 40.2 ± 6.1 vs. 39.1 ± 5.9; t103 = 0.90; p = 
0.37) between those who returned for the 5-year 
follow up (N = 68) and those were lost to follow up 
at any point since baseline (N = 37). There were 
statistically significant differences in SES (1.6 ± 0.8 
vs. 2.2 ± 1.1; z = –2.99; p = 0.003) and age at onset 
of BP-I disorder (4.6 ± 3.3 vs. 6.8 ± 3.7 years; z = –
3.16; p = 0.002) between the two groups. Those who 
returned for follow up came from a higher SES 
bracket and had an earlier age at onset. 
At follow up, returning subjects were 14.9 ± 3.8 
years old and had an average age at BP onset of 4.6 
± 3.3 years. The median duration of BP disorder at 
follow up was 10 years (interquartile range: 7 to 14), 
and 54% of subjects had reported ultra-rapid or 
ultradian cycling during their lifetime. 
 
 
 
 
 
 
FIGURE 1 
 
 
As shown in Figure 1, 19% (N = 13) of the returning 
subjects with BP-I disorder at baseline were euthymic 
(i.e., syndromatic and symptomatic remission) during 
the last year. The other 81% (N = 55) of subjects fell 
into three categories: those who continued to meet 
full diagnostic criteria for BP-I disorder (N = 34, 
50%) (i.e., syndromatic persistence), those who 
continued to have persistent subthreshold BP-I 
disorder (n = 9, 13%), and those who had full (N = 
9, 13%) or subthreshold (N = 3, 5%) major 
depression (i.e., symptomatic persistence). 
Of the euthymic subjects, none were receiving 
treatment. Of the 57 subjects who had met with full 
BP-I at the 4-year follow up, six were lost to follow 
up, nine remitted, 11 had subthreshold BP-I or full 
or subthreshold major depressive disorder, and 31 
maintained full BP-I at the 5-year follow up. Of the 
five subjects who were euthymic at the 4-year follow 
up without treatment, two were lost to follow up, one 
remained euthymic, one had full BP-I at 5-year 
follow up, and one had full major depressive disorder 
at follow up. 
 
Demographic characteristics 
There were no significant differences in sex, 
ethnicity, age, or SES between those with 
syndromatic persistence, symptomatic persistence, 
and syndromatic and symptomatic remission (Table 
1). 
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TABLE 1. Demographic characteristics of subjects with syndromatic and symptomatic remission, syndromatic persistence, and 
syndromatic persistence 
 Syndromatic and 
Symptomatic 
Remission (N=13) 
Symptomatic 
Persistence 
(N=21) 
Syndromatic 
Persistence (N=34) 
  
 N (%) N (%)  N (%) Test Statistic p-Value 
Sex (male) 10 (77) 14 (67) 27 (79) 2
2χ 1.16  0.56 
Caucasian 13 (100) 20 (95) 33 (97) Exact 1.00 
 Mean±SD Mean±SD Mean±SD   
Age at baseline[range] 11.5±3.6[4-16]  9.2±3.5[4-17] 9.3±3.4[4-17]  F(2, 65)=2.14 0.13
 
Age at follow-up[range] 16.9±4.2[9-22] 14.5±3.8[9-23] 14.4±3.6[7-23]  F2, 65=2.24 0.11 
SES 1.5±1.0 2.0±1.0 1.8±1.0 2
2 2.68   0.26 
Note. Data are presented as mean±standard deviation or N (%). 
 
 
 
 
 
TABLE 2. Characteristics of bipolar disorder 
 Syndromatic and 
Symptomatic 
Remission (N=13) 
Symptomatic 
Persistence (N=21) 
Syndromatic 
Persistence (N=34) 
  
 Median (Q1, Q3)† Median (Q1, Q3) Median (Q1, Q3) Test Statistic p-Value 
Baseline Duration 3 (1, 7) 3 (2, 6) 5 (2, 7)  2
2χ 1.16
 0.56 
Lifetime duration 7 (4, 9) 8 (5, 10) 10 (7, 14)*,‡,§
 
 2
2χ 9.15  
0.01 
 Mean±SD Mean±SD Mean±SD   
Baseline # of symptoms 5.5±1.3 5.8±1.1 6.3±0.9*,‡ F2, 65=3.41 0.04 
Lifetime # of symptoms 6.1±0.9 6.0±1.0 6.7±0.7*,‡,§,** F2, 65=5.25 0.008 
 N (%) N (%) N (%)   
Baseline ultra-rapid or ultradian 
cycling 
5 (38) 5 (24) 13 (39) 2
2χ 1.47
 0.48 
Lifetime ultra-rapid or ultradian 
cycling 
7 (54) 8 (38) 22 (65) 2
2χ 3.61
 0.17 
Severe impairment at baseline 7 (54) 14 (67) 25 (74) 2
2χ 1.64  0.44 
†Ql = 1st (25th percentile), Q3  = 3rd quartile (75th percentile) 
‡Compared with syndromatic and symptomatic remission 
§Compared with symptomatic persistence 
*p < 0.05, **p < 0.005  
 
 
 
Characteristics of Bipolar-I Disorder 
There were no significant differences in baseline 
duration of BP-I disorder across the three groups 
(syndromatic/symptomatic remission, symptomatic 
persistence, and syndromatic persistence), but there 
were significant differences in lifetime duration of 
BP-I disorder (Table 2). Those with syndromatic 
persistence had a significantly longer lifetime 
duration compared with the other two groups. There 
were no significant differences in the rate of subjects 
with baseline or lifetime ultra-rapid (≥ 20 episodes 
per year) or ultradian (≥ 300 episodes per year) 
cycling (see Table 2). The three groups significantly 
differed in both baseline and lifetime number of 
symptoms (see Table 2). Those with syndromatic 
persistence had significantly more baseline 
symptoms compared with those with full remission 
and more lifetime symptoms compared with the two 
other groups. Examining severe impairment at 
baseline, there were no significant differences among 
the three groups (see Table 2). 
 
Psychiatric disorders at follow up 
At follow up, there were significant differences in the 
1-year prevalence of major depressive disorder 
(Exact, p < 0.001), attention-deficit/hyperactivity 
disorder (ADHD) (χ22 = 13.42, p = 0.001), 
oppositional defiant disorder (χ22 = 12.75, p = 0.002), 
and conduct disorder/antisocial personality disorder 
(χ22 = 9.76, p = 0.008) among the three groups 
(Figure 2). Subjects with symptomatic persistence 
had significantly higher 1-year prevalence of major 
depressive disorder, ADHD, and oppositional 
defiant disorder compared with those with 
syndromatic and symptomatic remission. Subjects 
with syndromatic persistence had significantly higher 
1-year prevalence of all four psychiatric disorders 
compared with those with syndromatic and 
symptomatic remission. They also had a significantly 
higher 1-year prevalence of conduct 
disorder/antisocial personality disorder compared 
with those with symptomatic persistence. 
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FIGURE 2 
 
 
 
 
 
 
FIGURE 3 
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Global and school functioning 
At the 5-year follow up, there were significant 
differences in overall level of functioning within the 
past month, as measured by the GAF (F2, 65 = 25.85, 
p < 0.001), with subjects with syndromatic 
persistence having significantly more impaired scores 
than the other two groups and those with 
symptomatic persistence having significantly more 
impaired scores than those with syndromatic and 
symptomatic remission (Figure 3, A). 
There were significant differences among the three 
groups in the 1-year prevalence of being placed in a 
special class (χ22 = 7.08, p = 0.03), but not in the 1-
year prevalence of repeating a grade (Exact, p = 0.55) 
or receiving extra help (χ22 = 3.07, p = 0.22) (Figure 
3, B). Those with syndromatic persistence had a 
significantly higher 1-year prevalence of being placed 
in a special class compared with the other two 
groups. 
 
 
 
 
 
 
FIGURE 4 
 
 
 
Family history of psychiatric disorders 
We found no significant differences in family history 
of major depressive disorder (Exact, p = 0.81), BP-I 
disorder (χ22 = 1.14, p = 0.56), ADHD (χ22 = 1.14, p 
= 0.56), oppositional defiant disorder (χ22 = 5.92, p = 
0.05), conduct disorder/antisocial personality 
disorder (χ22 = 0.21, p = 0.90), multiple anxiety 
disorders (χ22 = 2.13, p = 0.34), or substance 
dependence (χ22 = 0.98, p = 0.61) across the three 
groups (Figure 4, A). 
In addition to family history of psychiatric 
disorders, we also examined the rates of mood 
disorders in the first-degree relatives of our 
probands. There were no significant differences in 
the rates of major depressive disorder (χ22 = 0.20, p 
= 0.91), BP-I disorder (χ22 = 1.11, p = 0.58), or any 
mood disorder (χ22 = 0.35, p = 0.84) among first-
degree relatives of probands with syndromatic and 
symptomatic remission, first-degree relatives of 
probands with symptomatic persistence, and first-
degree relatives of probands with syndromatic 
persistence (Figure 4, B).  
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Discussion 
Although there were more similarities than 
differences from the 4-year follow up to the 5-year 
follow up, some differences are of note. Our 
groupings from the 4-year follow up differed in two 
ways. In the 5-year follow up, we do not have 
treatment data to indicate how many youth of the 
euthymic group were receiving treatment for their 
disorder. Thus, the euthymic group in the 5-year 
follow up includes treated and untreated individuals. 
In addition, in the 4-year follow up, we report on the 
persistence of major depression, but in the 5-year 
follow up, we report on the persistence of depression 
by indicating rates of both full and subthreshold 
depression. As reported by Vaudreuil et al. (10), 
subthreshold states of pediatric BP disorder are 
highly morbid in themselves and, if present, should 
not be considered remission. Few longitudinal 
studies of pediatric BP consider the persistence of 
full and subsyndromal mania as well as full and 
subsyndromal depression. Thus, we have reported 
on persistence including both subsyndromal mania 
and depression. 
In the 4-year longitudinal study, 73.1% of subjects 
continued to meet for full BP-I disorder at the time 
of the follow-up assessment. In the 5-year study, that 
group represents 50% of the sample. In contrast, in 
the first follow-up group, 5.1% had depression 
without mania, whereas at the 5-year follow up, 18% 
had depression without mania. In addition, the 
subthreshold mania group grew from 6.4% to 13%. 
Taken together, this suggests a waxing waning course 
between full and subthreshold mania as well as 
between mania and depression. In both follow ups, a 
minority of the group was euthymic, 15.4% at the 4-
year follow up, and 19% at the 5-year follow up. 
The remitted patients in this 5-year follow up are 
older than the other groups, but the age ranges are 
similar, and this difference in mean does not reach 
statistical significance (mean age, 16.9 vs. 14.5 and 
14.4). However, if this trend were to continue, it 
could indicate that age brings an improving course 
for a subset of patients. Evaluating predictors of 
improvement and linking an improving trajectory to 
treatment would be useful for future study. 
Ultimately, this 5-year longitudinal follow-up study 
extended our previous 4-year follow-up findings (4) 
which documented the persistence of pediatric BP-I 
disorder. Our original follow-up study’s findings 
indicated that the overwhelming majority of youth 
with BP-I disorder at baseline continued to meet full 
DSM-IV diagnostic criteria for BP-I disorder at 
follow up (i.e., syndromatic persistence) or either 
subthreshold (13%) BP-I disorder or full or 
subthreshold (18%) major depression. The current 
study’s results further document the high persistence 
of BP-I spectrum symptomatology in BP-I youth, 
including subsyndromal manifestations of mania and 
major depressive disorder. These results provide 
compelling evidence of the morbidity and 
dysfunction associated with pediatric BP-I disorder 
supporting efforts for early identification and 
treatment of this disabling disorder. 
The high level of persistence documented in our 
sample of youth with BP-I disorder are consistent 
with findings reported in the pioneering work by 
Geller et al. (11) who followed-up children with 
pediatric onset BP disorder at 6, 12, and 18 months, 
and 2, 3, 4, 5, 6, and 8 years to assess the stability of 
the BP diagnosis in 115 children diagnosed in the 
prepubertal years (average age of diagnosis, 7.3±3.5 
years). The 2-year follow-up re-ascertained 89 
subjects and the 4-year follow up 86, and both of 
these studies reported high rates of persistence 
including assessment of both full and subthreshold 
states of both mania and depression. These authors 
concluded that their findings validated “the 
existence, long-episode duration, and chronicity of 
child mania.” (11). These reports support the 
importance of assessing subthreshold states of mania 
and depression at follow up. 
At the 8-year follow up by Geller et al., 54 subjects 
were aged 18 years or older, and 44.4% of that group 
met full criteria for an episode of mania after the age 
of 18 years at the follow-up interview. Recovery in 
this study was defined as eight consecutive weeks 
without meeting full DSM-IV criteria for mania, and 
remission was defined as two to seven weeks without 
meeting full DSM-IV criteria for mania. This study 
did not address subthreshold states of mania or the 
presence of full or subthreshold depression. 
Although 44.4% strongly supported continuity of 
pediatric BP disorder onto the adult years, subjects 
who had subthreshold symptoms of mania or full or 
subthreshold depression were not included in this 
outcome measure. This study provides important 
validation that pediatric onset BP disorder persists 
onto the adult years. 
Our findings are also consistent with those of 
Birmaher et al. (3) and the Course and Outcome of 
Bipolar Youth longitudinal study. In their 2-year 
follow-up study of 152 children and adolescents with 
BP disorder, these authors reported that 50% of their 
subjects had at least one syndromal recurrence and 
had syndromal or subsyndromal symptoms during 
60% of the follow-up time. The authors included BP 
spectrum diagnoses and defined BP-NOS as the 
presence of an abnormal mood state with change in 
functioning for at least four hours within one 24-
hour period for four different days lifetime, that was 
either elated (plus two associated symptoms of 
mania) or irritable (plus three associated symptoms 
of mania). In this study, 45% of subjects with BP-
NOS switched to BP- or BP-II with the median time 
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to conversion of 58 weeks (12). This study highlights 
the importance of assessing and following 
subthreshold symptoms of BP disorder in youth. 
The Longitudinal Assessment of Mania Symptoms 
(LAMS) study (13) followed 703 children aged seven 
to 12 years with manic symptoms based on a parent-
completed questionnaire. The majority of this 
sample, 77%, did not meet the criteria for any BP 
disorder, even BP-NOS as defined by the Course and 
Outcome of Bipolar Youth study. In this study, 15% 
of the children with manic symptoms showed high 
and rising or unstable symptoms of mania over time, 
suggesting a worsening course. This study provides 
useful information about children with manic 
symptoms who do not meet criteria for a BP disorder 
diagnosis at baseline, and the findings suggest that a 
subset of children with manic symptoms, but no 
diagnosis, may be at risk for a worsening course. 
Highly consistent with our previously reported 
findings (4), in our 4-year follow-up study, persistent 
and non-persistent cases at the 5-year follow-up 
mark had similarly high levels of psychiatric 
comorbidity, familiality of mood disorders, and 
school dysfunction rates. These poor functional 
outcomes are consistent with the studies of pediatric 
onset BP (14) and suggest the importance of 
including functional correlates in follow-up studies in 
addition to symptoms of mania and depression. 
Our findings of high levels of subthreshold 
persistence are noteworthy. Many studies of pediatric 
and adult BP disorder document the familiality, 
morbidity, and disability associated with 
subthreshold forms of BP-I disorder. We recently 
documented similar familial underpinnings for 
subsyndromal and full pediatric BP disorder (15). 
Using data from a community sample, Lewinsohn et 
al. (16) reported that youth with subthreshold BP-I 
disorder had impairment, comorbidity, and suicide 
attempts that were as severe as those with a full BP 
diagnosis. Adult studies have similar findings. For 
example, the National Comorbidity Survey of more 
than 9000 adults (17) reported that subthreshold BP 
disorder in adults is associated with high morbidity 
and disability. More clinical and scientific attention is 
needed to further characterize and intervene in 
subthreshold BP-I disorder. 
 
Limitations 
Our findings should be considered in the context of 
methodological limitations. Although we did not 
administer structured diagnostic interviews directly 
to children younger than 12 years of age, a clinical 
diagnosis of BP-I in the index children was 
corroborated by clinical assessment by an expert 
clinician before study inclusion (18). In addition, as 
the mean age at follow up was 15 years, most subjects 
underwent direct structured interview at follow up; 
however, 15 subjects were still younger than 12 years, 
and in those cases, diagnoses were obtained from 
maternal interview only, whereas for older subjects, 
we established diagnoses by combining parent and 
child reports. To support this practice, in the past, we 
have examined the concordance between mother and 
child reports for the diagnosis of pediatric BP 
disorder. In a 2009 report (19), of 98 pairs from two 
family studies of pediatric BP disorder, only four had 
a positive youth report combined with a negative 
maternal report. Of the 98, the majority, 59 pairs, 
were concordant (both mother and child reported 
the diagnosis) and 35 were discordant (the mother 
endorsed BP disorder, but the child did not). An 
analysis of the 35 concordant and discordant groups 
found no differences in onset, duration, or 
impairment of mania; rates of psychiatric 
hospitalization; cognitive variables; or rates of 
disorders in family members. We concluded that 
maternal reports, which were more common than 
youth-alone reports, are informative in the diagnosis 
of pediatric BP disorder, lending support to their use 
in our younger than 12 years group of subjects. Thus, 
for the current 5-year follow up, data were combined 
such that endorsement of a diagnosis by either the 
parent or the child resulted in a positive diagnosis. 
Although some of the sample was lost to follow up 
after 5 years, few differences (age of onset of BP 
disorder and SES) between those lost to follow up 
and those included in the study were found. Because 
this sample was clinically referred and primarily 
white, these results may not generalize to non-
referred children or to families of other ethnic 
groups. Our definition of persistence and remission 
by the presence of full or subthreshold syndromes of 
mania or depression occurring in the past year at the 
time of follow up differed from those used by other 
investigators (3, 5-6) who defined remission as an 8-
week period of loss of full syndrome. Although the 
establishment of the best definition of remission and 
persistence for pediatric BP-I disorder awaits 
additional research, we consider our definition to be 
a strength as it captures a clinically meaningful time 
period and symptom picture. 
 
Clinical significance 
Despite these considerations, this 1-year extension of 
a previously reported longitudinal 4-year follow-up 
study onto mid adolescence confirms the high level 
of persistence of pediatric BP-I disorder. In addition 
to the high levels of persistence of the full 
syndromatic persistence of BP-I disorder, we 
confirmed previous findings showing high levels of 
persistence of subthreshold BP-I disorder as well as 
full and subthreshold states of depression. These 
results contribute to a growing scientific literature 
documenting the high morbidity and persistence of 
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pediatric BP-I disorder from childhood onto late 
adolescence and young adulthood. Our findings 
emphasize the critical need for early identification 
and appropriate interventions for children with BP-I 
and associated disorders. 
Post et al. (20) demonstrated that more adverse 
outcomes among adults with BP disorder is 
associated with early-onset as well as delayed 
treatment. Early identification of both full and 
subsyndromal presentations of the disorder, as well 
as early intervention, is imperative for improved 
outcomes. The importance of subsyndromal states is 
increasingly recognized, which will facilitate early 
identification and can lead to earlier treatment. There 
are currently many United States Food and Drug 
Administration (US FDA)-approved medications for 
the treatment of pediatric BP disorder. These 
approved medications include, for manic or mixed 
states in youth ages 13 to 17 years, lithium and 
olanzapine. For manic or mixed states in youth ages 
10 to 17 years, US FDA-approved medications 
include risperidone, aripiprazole, and asenapine. 
Quetiapine is FDA-approved as monotherapy or as 
adjunct to lithium or divalproex sodium, for manic 
states, in youth age 10 to 17 years, and lurasidone is 
approved for BP depression in youth age 10 to 17 
years (21). However, clinicians may be reluctant to 
extend these treatments to younger patients. 
In addition, the second-generation antipsychotic 
medications are fraught with adverse effects such as 
weight gain—which can affect adherence and 
increased risk for cardiovascular disease and 
metabolic disorders (22-24). Other FDA-approved 
treatments for BP include mood stabilizers such as 
lithium. However, these medications have shown 
only moderate effectiveness in children and 
adolescents and is fraught with both serious and 
annoying adverse effects which limit its use, such as 
acne, weight gain, and need for regular blood test 
monitoring (25, 26). Studies examining the 
ameliorating effects of complementary and 
alternative supplements provide promising results 
and may prove especially useful in cases of mild to 
moderate illness as well as for very young children, in 
whom clinicians may wish to avoid exposure to 
medications which have known and unknown 
adverse effects. According to our pilot and interim 
analyses (27, 28), the use of natural supplements such 
as omega-3 fatty acids, inositol, and N-acetylcysteine 
produces positive improvements in the reduction of 
both manic and depressive symptoms in children and 
adolescents. If confirmed, these natural treatments 
could provide clinicians with a safe alternative for 
some cases of early onset of BP disorder, thus 
mitigating persistence and morbidity. 
 
 
Future Directions 
Considering the significant amount of longitudinal 
data we have collected through the past 5 years of 
follow up, we plan to examine whether critical 
measures from baseline predict the number of 
symptoms presented by a patient, or the group 
assignment of a patient, at follow up. Such measures 
could include specific diagnoses, severity in 
symptoms, cognitive measures, GAF, school 
attainment, SES, or age. 
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